🧠 Scientists Discover the Hidden Molecular Switch That Keeps Alzheimer's Inflammation Stuck in Overdrive

Researchers at Scripps Research Institute have identified a precise molecular mechanism that explains why the brain's immune system becomes trapped in a state of chronic, destructive inflammation in Alzheimer's disease. The discovery, published in Cell Chemical Biology, reveals that a single chemical modification to a protein called STING — at a specific building block known as cysteine 148 — acts as an "on switch" that cannot turn itself off.

The brain has its own built-in immune defenses, and STING normally serves as an early-warning system against infections. But in Alzheimer's patients, the team found that STING undergoes a process called S-nitrosylation (SNO), where a nitric oxide-related molecule latches onto cysteine 148. This transforms STING into a hyperactive form — dubbed "SNO-STING" — that clusters into large complexes and continuously pumps out inflammatory signals. The researchers confirmed elevated levels of this rogue protein in postmortem human brain tissue, in human stem cell-derived brain immune cells, and in mouse models of the disease.

What makes this cycle particularly vicious is that the very protein clumps associated with Alzheimer's — amyloid-beta and alpha-synuclein — can themselves trigger the S-nitrosylation of STING. Aging, air pollution, and even wildfire smoke further fuel the process by increasing nitric oxide in the brain. The result is a self-perpetuating "SNO-STORM": inflammation generates more NO, which modifies more STING, which drives even more inflammation, gradually destroying the synapses neurons use to communicate.

— A single amino acid (cysteine 148) on the STING protein is the exact site of the damaging modification
— Blocking SNO-STING formation in mice significantly reduced neuroinflammation
— Crucially, synaptic connections between neurons were protected from degradation — the same connections whose loss correlates with cognitive decline
— Unlike broad anti-inflammatory drugs, targeting cysteine 148 quiets only the pathological overactivation while leaving normal immune function intact
— The same pathway was confirmed active in human Alzheimer's brain tissue and stem-cell models

"This is a new and important therapeutic target for Alzheimer's disease," said senior author Stuart Lipton, the Step Family Foundation Endowed Chair at Scripps Research and a clinical neurologist. "It's exciting to see that blocking this switch in mice reduces inflammation and protects the very brain cell connections that are lost in Alzheimer's."

Why it matters: Alzheimer's affects over 55 million people worldwide, yet nearly all clinical trials targeting amyloid plaques have failed or shown marginal benefit. This discovery shifts the focus to neuroinflammation as a driver — not just a bystander — of the disease. The fact that the target is a single, well-defined amino acid means drug developers have an unusually clean bullseye. Lipton's team is already working on small-molecule drugs designed to sit on cysteine 148 and prevent the SNO modification, potentially offering the first therapy that breaks the inflammation cycle without crippling the immune system.

📄 Original paper (Cell Chemical Biology): https://www.cell.com/cell-chemical-biology/fulltext/S2451-9456(26)00109-1
📖 Readable summary (ScienceDaily): https://www.sciencedaily.com/releases/2026/05/260530053424.htm

#Alzheimers #Neuroscience #Neuroinflammation #STING #DrugDiscovery